IDiyas

For the Inventor, By the Inventor

Shanghai, China

Jijun Yuan

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Jiangsu, CN (2013)
  • Shanghai, CN (2016 - 2024)

Company Filing History:

goldMedal5 out of 100 
 
Shanghai Hengrui Pharmaceutical Co., Ltd.
 patents
silverMedal5 out of 159 
 
Jiangsu Hengrui Medicine Company Ltd.
 patents
bronzeMedal1 out of 2 
 
Shanghai Genbase Biotechnology Co., Ltd.
 patents
4. 1 out of 8 
 
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
 patents
5. 1 out of 1 
 
The Fourth Military Medical University Xi'an
 patent
6. 1 out of 1 
 
Shanghai Genbase Biotech Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):
1. 12037409 - Antibody specifically bound to glycosylated CEACAM5 (2024-07-16),
2. 11365255 - PD-1 antibody, antigen-binding fragment thereof, and medical application thereof (2022-06-21),
3. 11266688 - Single-chain antibody specifically binding MG7, highly glycosylated CEA and use thereof in detection and therapy (2022-03-08),
4. 10344090 - PD-1 antibody, antigen-binding fragment thereof, and medical application thereof (2019-07-09),
5. 10206980 - IL-15 heterodimeric protein and uses thereof (2019-02-19),
6. 9458219 - Human insulin analogue and acylated derivative thereof (2016-10-04),
7. 8609622 - C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof (2013-12-17),

Title: Jijun Yuan: Innovator in Antibody Development

Introduction

Jijun Yuan, a prominent inventor based in Shanghai, China, has made significant advancements in the field of biotechnology. With a total of 7 patents to his name, Yuan has focused on developing innovative antibodies that have critical medical applications.

Latest Patents

His latest patents include groundbreaking developments such as an antibody specifically bound to glycosylated CEACAM5. This patent outlines an antibody that binds with precision to glycosylated CEACAM5, along with the methods for creating humanized versions of this antibody. Another notable invention is a PD-1 antibody and its antigen-binding fragment, which provides substantial medical applications. This patent describes how the human PD-1 antibody, along with its variants and pharmaceutical compositions, can be utilized in the treatment of various diseases and disorders.

Career Highlights

Yuan's career includes notable contributions while working at reputable companies such as Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. These positions have allowed him to collaborate on vital projects that contribute to the advancement of medical biotechnology.

Collaborations

During his career, Jijun Yuan has worked alongside talented individuals like Lianshan Zhang and Xiangdong Qu. Their collaborative efforts have undoubtedly fortified his research initiatives and contributed to the advancements in antibody technology.

Conclusion

Jijun Yuan stands out as an innovative force in the biotechnology sector. With his extensive patent portfolio and collaborations with leading professionals, he has crafted solutions that address significant medical challenges. His work continues to influence the landscape of antibody development and its potential to improve patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…